Bristol-Myers Squibb Co (BMY) Shares Bought by Dividend Assets Capital LLC

Dividend Assets Capital LLC grew its position in Bristol-Myers Squibb Co (NYSE:BMY) by 33.5% in the third quarter, Holdings Channel reports. The fund owned 17,670 shares of the biopharmaceutical company’s stock after buying an additional 4,435 shares during the quarter. Dividend Assets Capital LLC’s holdings in Bristol-Myers Squibb were worth $1,126,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Bristol-Myers Squibb by 0.3% in the second quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after purchasing an additional 333,685 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Bristol-Myers Squibb by 2.4% in the second quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock valued at $5,541,612,000 after purchasing an additional 2,367,864 shares in the last quarter. Dodge & Cox increased its holdings in shares of Bristol-Myers Squibb by 1.6% in the second quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after purchasing an additional 459,271 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Bristol-Myers Squibb by 16.2% in the third quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock valued at $1,711,689,000 after purchasing an additional 3,735,453 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Bristol-Myers Squibb by 3.9% in the second quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after purchasing an additional 910,496 shares in the last quarter. Institutional investors own 69.67% of the company’s stock.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Theodore R. Samuels II purchased 4,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was purchased at an average cost of $62.30 per share, with a total value of $249,200.00. Following the acquisition, the director now directly owns 22,000 shares in the company, valued at $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by insiders.

A number of analysts recently weighed in on BMY shares. Cowen reissued a “hold” rating and issued a $65.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, September 19th. Vetr raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 price target for the company in a report on Wednesday, September 27th. Jefferies Group reissued a “buy” rating and issued a $72.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, September 27th. UBS Group reissued a “buy” rating and issued a $72.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Finally, BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a report on Thursday, October 12th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $65.05.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $62.81 on Friday. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Co has a fifty-two week low of $46.01 and a fifty-two week high of $66.10. The company has a market cap of $102,800.00, a price-to-earnings ratio of 24.73, a price-to-earnings-growth ratio of 2.22 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same period in the prior year, the firm posted $0.77 EPS. Bristol-Myers Squibb’s revenue was up 6.7% on a year-over-year basis. equities analysts forecast that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 2.55%. The ex-dividend date is Thursday, January 4th. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is currently 62.99%.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.com-unik.info/2018/01/13/bristol-myers-squibb-co-bmy-shares-bought-by-dividend-assets-capital-llc.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit